麦德佩斯临床研究

最新新闻

• Mizuho Securities Maintains Medpace(MEDP.US) With Buy Rating, Raises Target Price to $700
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Baird Downgrades Medpace(MEDP.US) to Hold Rating, Raises Target Price to $547
  \u5e02\u573a\u8d44\u8baf · 2026/7/8
• 评级变动
  RBC Capital Initiates Medpace(MEDP.US) With Buy Rating, Announces Target Price $522
  \u5e02\u573a\u8d44\u8baf · 2026/3/3
• 评级变动
  Mizuho Securities Maintains Medpace(MEDP.US) With Buy Rating, Maintains Target Price $665
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  A Quick Look at Today's Ratings for Medpace(MEDP.US), With a Forecast Between $400 to $477
  \u5e02\u573a\u8d44\u8baf · 2026/4/25
• UBS Maintains Medpace(MEDP.US) With Hold Rating, Maintains Target Price $673
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• 评级变动
  Jefferies Maintains Medpace(MEDP.US) With Buy Rating, Raises Target Price to $560
  \u5e02\u573a\u8d44\u8baf · 2026/2/13
• 评级变动
  A Quick Look at Today's Ratings for Medpace(MEDP.US), With a Forecast Between $535 to $692
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  William Blair Maintains Medpace(MEDP.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/4/23
• Barclays Maintains Medpace(MEDP.US) With Hold Rating, Raises Target Price to $625
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Jefferies Maintains Medpace(MEDP.US) With Buy Rating, Cuts Target Price to $490
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• UBS Initiates Medpace(MEDP.US) With Hold Rating, Announces Target Price $673
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Mizuho Securities Maintains Medpace(MEDP.US) With Buy Rating, Raises Target Price to $665
  \u5e02\u573a\u8d44\u8baf · 2026/7/25
• 评级变动
  Barclays Upgrades Medpace(MEDP.US) to Hold Rating, Cuts Target Price to $500
  \u5e02\u573a\u8d44\u8baf · 2026/3/6
• 评级变动
  Mizuho Securities Maintains Medpace(MEDP.US) With Buy Rating, Raises Target Price to $586
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  William Blair Initiates Medpace(MEDP.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• RBC Capital Maintains Medpace(MEDP.US) With Buy Rating, Maintains Target Price $692
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Truist Financial Maintains Medpace(MEDP.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 评级变动
  RBC Capital Maintains Medpace(MEDP.US) With Buy Rating, Maintains Target Price $522
  \u5e02\u573a\u8d44\u8baf · 2026/4/16
• 评级变动
  Truist Financial Maintains Medpace(MEDP.US) With Hold Rating, Maintains Target Price $609
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• Medpace(MEDP.US) 10% Shareholder Sells US$15.36 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• Medpace(MEDP.US) 10% Shareholder Sells US$44.43 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Jefferies Maintains Medpace(MEDP.US) With Buy Rating, Maintains Target Price $560
  \u5e02\u573a\u8d44\u8baf · 2026/2/13
• Medpace(MEDP.US) 10% Shareholder Sells US$6.75 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/22

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。